The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of Blueprint Medicines Corp (NASDAQ: BPMC) was $127.96 for the day, down -0.19% from the previous closing price of $128.21. In other words, the price has decreased by -$0.19 from its previous closing price. On the day, 4.71 million shares were traded.
Ratios:
Our analysis of BPMC’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.75 and its Current Ratio is at 2.80. In the meantime, Its Debt-to-Equity ratio is 2.08 whereas as Long-Term Debt/Eq ratio is at 1.72.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 03 ’25 when Carter Percy H. sold 2,659 shares for $127.88 per share. The transaction valued at 340,033 led to the insider holds 54,206 shares of the business.
Albers Jeffrey W. sold 5,000 shares of BPMC for $505,692 on May 27 ’25. The Director now owns 146,630 shares after completing the transaction at $101.14 per share. On May 27 ’25, another insider, Albers Jeffrey W., who serves as the Director of the company, bought 5,000 shares for $101.14 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 14.72 while its Price-to-Book (P/B) ratio in mrq is 24.15.
Stock Price History:
Over the past 52 weeks, BPMC has reached a high of $128.34, while it has fallen to a 52-week low of $73.04. The 50-Day Moving Average of the stock is 28.44%, while the 200-Day Moving Average is calculated to be 34.49%.
Shares Statistics:
A total of 64.56M shares are outstanding, with a floating share count of 62.30M. Insiders hold about 3.67% of the company’s shares, while institutions hold 106.82% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by 3.0 analysts. The consensus estimate for the next quarter is -$0.29, with high estimates of -$0.11 and low estimates of -$0.57.
Analysts are recommending an EPS of between -$0.44 and -$0.44 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is $1.06, with 4.0 analysts recommending between $2.24 and -$0.16.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 17 analysts. It ranges from a high estimate of $180.1M to a low estimate of $165.1M. As of the current estimate, Blueprint Medicines Corp’s year-ago sales were $138.16MFor the next quarter, 17 analysts are estimating revenue of $191.05M. There is a high estimate of $203M for the next quarter, whereas the lowest estimate is $185.5M.
A total of 19 analysts have provided revenue estimates for BPMC’s current fiscal year. The highest revenue estimate was $773M, while the lowest revenue estimate was $706.5M, resulting in an average revenue estimate of $720.59M. In the same quarter a year ago, actual revenue was $508.82MBased on 19 analysts’ estimates, the company’s revenue will be $956M in the next fiscal year. The high estimate is $1.02B and the low estimate is $859M.
